Biotech

AD/PD™ 2027

Name: AD/PD™ 2027
Start: 2027-03-16
End: 2027-03-20
Location: Barcelona

The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference presents breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer’s, Parkinson’s, and related disorders. The event unites experts in neurodegenerative disease research and innovation, featuring sessions on mechanistic science, clinical…

Visit the official site Sponsorship open

84Speakers

21Sponsors

91On the bill · sessions

29Companies · in total

§I

Speakers

Programmed at AD/PD™, in alphabetical order.

Abraham Fisher

President

Agneta Nordberg

Angela Genge

Bart De Strooper

Beka Solomon

Israel

Bradley Boeve

Catherine Mummery

Charlotte Teunissen

Netherlands

Christian Haass

Claudio A. Cuello

Cynthia Lemere

Executive Organizer

Dag Aarsland

Dan Frenkel

Daniel Ferreira Padilla

David Holtzman

USA

Dennis Selkoe

USA

Dimitri Krainc

Donna Wilcock

USA

Elizabeth Head

Ezio Giacobini

Executive Organizer

Fabrizio Stocchi

Italy

Frank Laferla

§II

Agenda

Selected from 91 sessions on the bill.

TBA
AD-RIDDLE - REAL WORLD IMPLEMENTATION AND VALIDATION OF EARLY DETECTION TOOLS AND TAILORED INTERVENTIONS
TBA
AGING, APOE AND GBA1 DETERMINE HIPPOCAMPAL GENE RESPONSES TO LIPID DYSHOMEOSTASIS IN PD, LBD AND AD IN VIVO MODELS
TBA
AGING, APOE AND GBA1 DETERMINE HIPPOCAMPAL RESPONSES TO LIPID DYSHOMEOSTASIS IN PD, LBD AND AD IN VIVO MODELS
TBA
ALPHA-SYNUCLEIN SEEDING ACTIVITY IN THE OLFACTORY MUCOSA IN POST-COVID HYPOSMIA
TBA
A NOVEL GENE THERAPY APPROACH TO TARGET MICROGLIA IN VIVO
TBA
ANTI TAU THERAPIES: WHERE DO WE STAND?
TBA
APOE-DEPENDENT LIPID DYSREGULATION IN ALZHEIMER’S DISEASE
TBA
APOE PERIPHERAL SIGNATURES AND IMPLICATIONS TO NEURODEGENERATION
TBA
BEYOND AMYLOID - THE NEXT STEPS IN TREATMENTS FOR ALZHEIMER'S DISEASE

Intermission

Part the Second · For the Buyer

An audience of 29 companies, parsed from the program.

29 companies in attendance.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room

0All threespeak · spons · exh

20Sponsoringsponsor only

9Companies Speakingspeaker only

Speakers by seniority

Other roles84100%

Of 84 on the bill · classified by free-text title

Most-represented companies

Sponsors by tier

media partner8

38% of 21

unspecified13

62% of 21

Partner conferences

Listed on this event's own sponsor page

Alzheimer’s Association International Conference 2027· ChicagoJul 2027

AD/PD™ 2027

AD-RIDDLE - REAL WORLD IMPLEMENTATION AND VALIDATION OF EARLY DETECTION TOOLS AND TAILORED INTERVENTIONS

AGING, APOE AND GBA1 DETERMINE HIPPOCAMPAL GENE RESPONSES TO LIPID DYSHOMEOSTASIS IN PD, LBD AND AD IN VIVO MODELS

AGING, APOE AND GBA1 DETERMINE HIPPOCAMPAL RESPONSES TO LIPID DYSHOMEOSTASIS IN PD, LBD AND AD IN VIVO MODELS

ALPHA-SYNUCLEIN SEEDING ACTIVITY IN THE OLFACTORY MUCOSA IN POST-COVID HYPOSMIA

A NOVEL GENE THERAPY APPROACH TO TARGET MICROGLIA IN VIVO

ANTI TAU THERAPIES: WHERE DO WE STAND?

APOE-DEPENDENT LIPID DYSREGULATION IN ALZHEIMER’S DISEASE

APOE PERIPHERAL SIGNATURES AND IMPLICATIONS TO NEURODEGENERATION

BEYOND AMYLOID - THE NEXT STEPS IN TREATMENTS FOR ALZHEIMER'S DISEASE

29 companies in attendance.